CHIUN HSUDucreux, MichelMichelDucreuxZhu, Andrew XAndrew XZhuQin, ShukuiShukuiQinIkeda, MasafumiMasafumiIkedaKim, Tae-YouTae-YouKimGalle, Peter RPeter RGalleFinn, Richard SRichard SFinnChen, EthanEthanChenMa, NingNingMaHu, YouyouYouyouHuLi, LindongLindongLiANN-LII CHENG2023-05-052023-05-052023-022235-1795https://scholars.lib.ntu.edu.tw/handle/123456789/630859In the Phase 3 IMbrave150 trial (NCT03434379), atezolizumab + bevacizumab demonstrated a clinically meaningful survival benefit over sorafenib in patients with unresectable hepatocellular carcinoma (HCC), including those with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. We used IMbrave150 data to investigate the safety and risk of viral reactivation or flare in infected patients treated with atezolizumab + bevacizumab or sorafenib.enAtezolizumab; Bevacizumab; Post hoc analysis; Viral flare; Viral reactivation[SDGs]SDG3journal article10.1159/000525499368729212-s2.0-85149113122WOS:000848470600001https://api.elsevier.com/content/abstract/scopus_id/85149113122